ABSTRACT

Aim

Methicillin-resistant Staphylococcus aureus (MRSA) is an emergent pathogen which can colonize in nose and on the skin; lead sellulitis, impetigo and abscess and which can cause community and hospital-acquired serious infections. Treatment of MRSA infection encounters difficulties due to the resistance. Researchers continue to search for an alternative due to the limited treatment options. Tigecycline (GAR-936), a derivative of glycylcycline, is an agent accepted for the usage for treatment in recent years. In this study, it was aimed to investigate the in vitro susceptibility rate of MRSA strains isolated from various clinical specimens in microbiology laboratory of Abant Izzet Baysal University Faculty of Medicine.

Material and Methods

Minimum inhibitory concentration (MIC) of tigecycline were detemined with broth microdilution method for a total of 100 MRSA isolates.

Results

MIC values of tigecycline to the isolates were found between a range of 0.0625-4 μg/ml; according to this, 91 (91%) of the isolates were determined as susceptible and 3 (3%) were found as intermediate to tigecycline. The MIC₅₀ value was found 0.25 μg/ml and MIC₉₀ was 0.5 μg/ml.

Conclusion

Despite the higher resistance rate to tigecycline in comparison to data obtained from other studies of our country, the findings of our study shows that tigecycline is still an appropriate alternative in treatment of infections caused by MRSA in our hospital.